Powder: -20°C for 3 years | In solvent: -80°C for 2 years
AG 1295 是选择性血小板衍生生长因子受体酪氨酸激酶抑制剂。它能抑制 PDGFR 的自磷酸化,对 EGF 受体的自磷酸化无影响。
产品描述 | AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR. But it can not affects the autophosphorylation of the EGF receptor[1][2][3][4]. |
体外活性 | AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1]. |
体内活性 | AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibition of PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly reduces interstitial fibrosis as verified by a smaller Sirius-Red stained area, and by a reduced number of macrophages, and by the ED-A+ fibronectin deposition. It is also verified by the number of cells positive for alpha-smooth muscle actin[4]. |
分子量 | 234.3 |
分子式 | C16H14N2 |
CAS No. | 71897-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 60 mg/mL (256.08 mM), Need ultrasonic
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AG 1295 71897-07-9 Angiogenesis Tyrosine Kinase/Adaptors PDGFR Platelet-derived growth factor receptor RTK inhibit PDGF-receptor AG-1295 autophosphorylation Inhibitor AG1295 inhibitor